|
gptkbp:instanceOf
|
gptkb:drug
synthetic thyroid hormone
|
|
gptkbp:ATCCode
|
H03AA02
|
|
gptkbp:brand
|
gptkb:Cytomel
gptkb:Triostat
|
|
gptkbp:CASNumber
|
55-06-1
|
|
gptkbp:chemicalFormula
|
C15H11I3NNaO4
|
|
gptkbp:contraindication
|
gptkb:thyrotoxicosis
uncorrected adrenal insufficiency
|
|
gptkbp:discoveredBy
|
gptkb:Charles_R._Harington
|
|
gptkbp:discoveredIn
|
1952
|
|
gptkbp:eliminationHalfLife
|
2.5 days
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
liothyronine
|
|
gptkbp:IUPACName
|
sodium (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to thyroid hormone receptors
|
|
gptkbp:meltingPoint
|
205°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
672.96 g/mol
|
|
gptkbp:pregnancyCategory
|
A (Australia)
|
|
gptkbp:PubChem_CID
|
5819
DB00279
|
|
gptkbp:relatedTo
|
gptkb:levothyroxine
hormone
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
anxiety
weight loss
insomnia
palpitations
|
|
gptkbp:UNII
|
06LU7C9H1V
|
|
gptkbp:usedFor
|
hypothyroidism
myxedema coma
thyroid hormone replacement therapy
|
|
gptkbp:bfsParent
|
gptkb:levothyroxine
|
|
gptkbp:bfsLayer
|
7
|